Search results for "Reactions"

showing 10 items of 631 documents

Clinical evaluation of drug-induced hepatitis

2005

Objective: to ascertain the epidemiological characteristics, clinical symptoms, and evolution of drug-induced hepatitis over the last 22 years. Experimental design and subjects: an observational, retrospective study between 1982 and 1993, and prospective study between 1994 and 2003. All patients in our department diagnosed with having drug-induced hepatitis were studied analyzing epidemiological (age, sex, cases per year, hospitalization) and clinical features (previous liver disease, hepatic symptoms, laboratory results), and follow-up (complete recovery or chronicity). Results: a total of 61 patients were diagnosed as having drug-induced hepatitis, 26 men and 35 women (57%), mean age 52.4…

AdultMaleDrugmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsEpidemiologyEvolutionmedia_common.quotation_subjectLiver diseaseSex FactorsInternal medicineEpidemiologyHumansMedicineAcute hepatitisProspective cohort studyAgedRetrospective Studiesmedia_commonHepatitisClinical characteristicsbusiness.industryIncidence (epidemiology)Age FactorsGastroenterologyDrugsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryHospitalizationSpainFemaleObservational studyChemical and Drug Induced Liver InjurybusinessRevista Española de Enfermedades Digestivas
researchProduct

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine : a phase 2 randomised, placebo-control…

2012

Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine.In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were sup…

AdultMaleDrug-Related Side Effects and Adverse ReactionsPyridinesPopulationMedizinAdministration OralKaplan-Meier EstimatePlacebolaw.inventionYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodPiperidinesRandomized controlled triallawHumansMedicineAdverse effecteducationAgededucation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle AgedDose-ranging studymedicine.diseaseLasmiditanSerotonin Receptor Agonists3. Good healthTreatment OutcomechemistryTolerabilityMigraine030220 oncology & carcinogenesisAnesthesiaBenzamidesFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Lack of hepatitis B virus DNA sequences in sera from patients with acute and chronic liver diseases diagnosed as non-A, non-B-hepatitis

2008

— The sera of 15 individuals with transfusion-associated acute or chronic non A, non B hepatitis, which lacked hepatitis B virus markers, were tested for hepatitis B virus DNA by dot blot hybridization test. Three sera of two patients positive in this test, however, also gave positive results when the labeled plasmid was used as probe instead of labeled HBV-DNA, indicating false positive results in the initial test. In conclusion, the data indicated that sera of patients with confirmed non A, non B hepatitis do not contain DNA-sequences in the serum hybridizing with HBV-DNA.

AdultMaleHepatitis B virusAdolescentHepatitis Viral HumanDot blotmedicine.disease_causeChronic liver diseaseVirusPlasmidmedicineHumansFalse Positive ReactionsAgedHepatitis B virusHepatologybiologybusiness.industryMiddle AgedHepatitis Bmedicine.diseasebiology.organism_classificationHepatitis CVirologyHepadnaviridaeDNA ViralImmunologyFemaleViral diseasebusinessLiver
researchProduct

Falsely elevated intraocular pressure due to increased central corneal thickness

1999

PURPOSE: To evaluate whether ocular hypertensive subjects have a higher central corneal thickness than other individuals. METHODS: In this prospective study, 48 subjects with ocular hypertension, 63 patients with open-angle glaucoma, 56 nonglaucomatous patients with diabetes mellitus, and 106 control subjects were evaluated. Corneal thickness was measured by ultrasound pachymetry, and intraocular pressure was determined by Goldmann applanation tonometry. RESULTS: Central corneal thickness was significantly higher in the ocular hypertensive subjects, mean +/- S.D., 592+/-39 microm, than in the patients with glaucoma (536+/-34 microm), the nonglaucomatous patients with diabetes mellitus (550+…

AdultMaleIntraocular pressuremedicine.medical_specialtyprimary open-angle glaucomaAdolescentgenetic structuresEye diseaseOcular hypertensionGlaucomaCorneaCellular and Molecular NeurosciencePredictive Value of TestsCorneaOphthalmologyDiabetes mellitusHumansMedicineFalse Positive ReactionsProspective StudiesCorneal pachymetry[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansProspective cohort studyAgedUltrasonographyAged 80 and overmedicine.diagnostic_testdiabetesbusiness.industryMiddle Agedmedicine.diseaseSensory Systemseye diseasesSurgeryOphthalmologymedicine.anatomical_structureocular hypertensionFemalecentral corneal thicknesssense organsbusinessGlaucoma Open-Angle[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyintraocular pressure
researchProduct

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

2013

Abstract Background A combination of bortezomib (1.3 mg/m2), melphalan (5 mg/m2), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated. Patients and methods Fifty previously treated (median 2 previous lines) patients with myeloma (33 relapsed and 17 refractory) were assessed. The first 19 patients were treated with a twice-a-week (days 1, 4, 8, 11, ‘base’ schedule) administration while, in the remaining 31 patients, the three drugs were administered once a week (days 1, 8, 15, 22, ‘weekly’ schedule). Results Side-effects were predictable and manageable, with prominent haematological toxicity, and a better tox…

AdultMaleMelphalanmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSalvage therapyGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleBortezomibRefractoryRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalMelphalanMultiple myelomaDexamethasoneAgedRetrospective StudiesAged 80 and overBortezomibbusiness.industryHematologyMiddle Agedmedicine.diseaseBoronic AcidsRegimenTreatment OutcomeOncologyPyrazinesInjections IntravenousFemaleMultiple MyelomabusinessFollow-Up Studiesmedicine.drug
researchProduct

Caspofungin for the treatment of candidaemia in patients with haematological malignancies

2010

AbstractThis study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as …

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsNeutropeniaDrug-Related Side Effects and Adverse ReactionsCandidaemia; Caspofungin; Leukaemiamedicine.medical_treatmentAntineoplastic AgentsNeutropeniaEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundPharmacotherapyCandidaemiaCaspofunginInternal medicinemedicineHumansLeukaemiaProspective StudiescaspofunginProspective cohort studyMycosisFungemiaAgedChemotherapyHematologybusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeInfectious DiseaseschemistryHematologic NeoplasmsleukaemiaFemaleCaspofunginbusinessFungemia
researchProduct

Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma

2010

Patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy are still in relatively good clinical conditions and may still require second-line chemotherapy, which is frequently administered in daily clinical practice given to without solid scientific support.A retrospective survey was carried out including 40 patients with stage III or IV gemcitabine-refractory pancreatic carcinoma. Patients received standard FOLFIRI regimen biweekly until progression or unacceptable toxicity. Response evaluation criteria in solid tumors and National Cancer Institute common toxicity criteria were employed respectively for response and toxicity assessment.Six partial responses …

AdultMaleOncologyCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentLeucovorinIrinotecanBolus (medicine)Pancreatic cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineFOLFIRI RegimenHumansPancreatic carcinomaAgedRetrospective StudiesChemotherapybusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabinePancreatic NeoplasmsIrinotecanOncologyFluorouracilCamptothecinFemaleFluorouracilbusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicente…

2006

This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as third- or fourth-line therapy in a retrospective series of patients with metastatic colorectal cancer refractory to oxaliplatin and irinotecan. Patients and Methods: Most patients (90%) had been previously treated with adjuvant 5-fluorouracil/leucovorin, and all had received oxaliplatin-based regimens before receiving irinotecan- based second-line treatment. Sixty patients with irinotecan-refractory colorectal cancer received a regimen comprising weekly irinotecan 120 mg/m 2 as a 1-hour intravenous infusion and cetuximab 400 mg/m 2 infused over 2 hours as the initial dose and 250 mg/m 2 infus…

AdultMaleOncologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSettore MED/06 - Oncologia MedicaColorectal cancermedicine.medical_treatmentCetuximabAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisSurvival analysisAgedAged 80 and overChemotherapyCetuximabPerformance statusbusiness.industryGastroenterologyAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesOxaliplatinErbB ReceptorsIrinotecanSettore MED/18 - Chirurgia GeneraleRegimenOncologyCamptothecinFemaleEpidermal growth factor receptor Oxaliplatin Vascular endothelial growth factorColorectal Neoplasmsbusinessmedicine.drugClinical Colorectal Cancer
researchProduct

Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy)

2011

The aim of the study was to investigate factors involved in vaccination acceptance among healthcare workers (HCWs) and adverse reactions rates associated with pandemic influenza vaccination. The study was carried out in the major teaching hospital of Sicily from November 2009 to February 2010 on 2267 HCWs. A total of 407 (18%) HCWs were vaccinated against the 2009 pandemic influenza A (H1N1). A logistic regression analysis indicates an increased risk of non-vaccination against pandemic influenza in females (OR = 1.6; 95% CI = 1.3-2.1) compared to males, in nurses/technicians/administrative workers (OR = 1.7; 95% CI = 1.3-2.2) compared to doctors/biologists, and in HCWs who were non-vaccinat…

AdultMalePandemic influenza vaccination healthcare workers adverse reactionsHealth PersonneleducationOrthomyxoviridaeSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeTeaching hospitalSurveys and QuestionnairesEnvironmental healthInfluenza HumanHealth careInfluenza A virusmedicineHumansHospitals TeachingAdverse effectSicilyGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthPandemic influenzavirus diseasesMiddle Agedbiology.organism_classificationVaccinationLogistic ModelsInfectious DiseasesInfluenza VaccinesMultivariate AnalysisImmunologyMolecular MedicineFemaleViral diseasebusinessVaccine
researchProduct

Local reactions to tick bites

2008

A retrospective histological and immunohistochemical study has been carried out in 25 cases of tick bites recorded in our Departments. The samples that included an attached tick showed a cement cone anchoring the mouthparts to the skin and a blood-soaked, spongiform appearance of the superficial dermis, with a mild neutrophilic and eosinophilic infiltration. The vessels displayed a loose multilayered endothelial proliferation, with plump endothelia, permeated with erythrocytes. A few of them were severed, allowing copious blood extravasation. The established lesions included the following: erythema chronicum migrans-like cases, foreign body granulomas-sometimes containing remnants of the mo…

AdultMalePathologymedicine.medical_specialtyHistologyErythemaAdolescentAlopecia AreataT-LymphocytesDermatologyBiologySettore MED/08 - Anatomia PatologicaSkin DiseasesLymphoid hyperplasiaPathology and Forensic MedicineHost-Parasite InteractionsLymphocytic InfiltrateDermisPseudolymphomamedicineSettore MED/35 - Malattie Cutanee E VenereeAnimalsHumansChildAgedRetrospective StudiesAged 80 and overB-LymphocytesIxodeslocal reactionInsect Bites and StingsHistologyGeneral MedicineAnatomyHyperplasiaMiddle Agedmedicine.diseaseHistology; local reactions; tick attacksArthropod mouthpartsExtravasationmedicine.anatomical_structuretick attacksErythema Chronicum MigransFemalemedicine.symptom
researchProduct